Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodolphe Thiebaut

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Investigation|March 8, 2019
Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccinationEléna Gonçalves, Olivia Bonduelle, Angèle Soria, et al.
Plos One|December 1, 2018
HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidatesAnne-Laure Flamar, Henri Bonnabau, Sandra Zurawski, et al.
AIDS (London, England)|October 17, 2018
Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trialRomain Palich, Jade Ghosn, Antoine Chaillon, et al.
AIDS (London, England)|May 11, 2010
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study, Colette Smith, Caroline A Sabin, et al.
Journal of Virology|March 25, 2016
Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman PrimatesRoger Le Grand, Nathalie Dereuddre-Bosquet, Stefania Dispinseri, et al.
Plos Medicine|November 1, 2011
Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin AmericaBenjamin H Chi, Constantin T Yiannoutsos, Andrew O Westfall, et al.
Eclinicalmedicine|December 9, 2024
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)Yves Levy, Christiane Moog, Aurélie Wiedemann, et al.
JAMA|April 7, 2011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
The Lancet. HIV|December 5, 2017
Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trialCollins C Iwuji, Joanna Orne-Gliemann, Joseph Larmarange, et al.
The Journal of Infectious Diseases|August 15, 2018
Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIVFelicity C Fitzgerald, Edouard Lhomme, Kathryn Harris, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Investigation|March 8, 2019
Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccinationEléna Gonçalves, Olivia Bonduelle, Angèle Soria, et al.
Plos One|December 1, 2018
HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidatesAnne-Laure Flamar, Henri Bonnabau, Sandra Zurawski, et al.
AIDS (London, England)|October 17, 2018
Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trialRomain Palich, Jade Ghosn, Antoine Chaillon, et al.
AIDS (London, England)|May 11, 2010
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study, Colette Smith, Caroline A Sabin, et al.
Journal of Virology|March 25, 2016
Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman PrimatesRoger Le Grand, Nathalie Dereuddre-Bosquet, Stefania Dispinseri, et al.
Plos Medicine|November 1, 2011
Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin AmericaBenjamin H Chi, Constantin T Yiannoutsos, Andrew O Westfall, et al.
Eclinicalmedicine|December 9, 2024
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)Yves Levy, Christiane Moog, Aurélie Wiedemann, et al.
JAMA|April 7, 2011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
The Lancet. HIV|December 5, 2017
Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trialCollins C Iwuji, Joanna Orne-Gliemann, Joseph Larmarange, et al.
The Journal of Infectious Diseases|August 15, 2018
Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIVFelicity C Fitzgerald, Edouard Lhomme, Kathryn Harris, et al.
Pageof 6